相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination
Radha Gopal et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Markers Predicting Response to Bacillus Calmette-Guerin Immunotherapy in High-Risk Bladder Cancer Patients: A Systematic Review
Tahlita C. M. Zuiverloon et al.
EUROPEAN UROLOGY (2012)
Association of Polymorphisms in Oxidative Stress Genes with Clinical Outcomes for Bladder Cancer Treated with Bacillus Calmette-Guerin
Hua Wei et al.
PLOS ONE (2012)
Maintenance therapy with bacillus Calmette-Guerin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer
Shiro Hinotsu et al.
BJU INTERNATIONAL (2011)
The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guein can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands
Jun Miyazaki et al.
BJU INTERNATIONAL (2011)
Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guerin and Prospective Use in Immunotherapy of Bladder Cancer
Yi Luo et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)
IL-17 production by gamma delta T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guerin treatment against bladder cancer
Ario Takeuchi et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update
Marko Babjuk et al.
EUROPEAN UROLOGY (2011)
Bacillus Calmette-Guerin treatment of non-muscle invasive bladder cancer
Richard J. Sylvester
INTERNATIONAL JOURNAL OF UROLOGY (2011)
A Review of Current Guidelines and Best Practice Recommendations for the Management of Nonmuscle Invasive Bladder Cancer by the International Bladder Cancer Group
Maurizio Brausi et al.
JOURNAL OF UROLOGY (2011)
Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer
Alon Z. Weizer et al.
WORLD JOURNAL OF UROLOGY (2011)
Mycobacterium bovis Bacillus Calmette-Guerin-Induced Macrophage Cytotoxicity against Bladder Cancer Cells
Yi Luo et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-GuErin
Akira Joraku et al.
BJU INTERNATIONAL (2009)
An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer
Per-Uno Malmstrom et al.
EUROPEAN UROLOGY (2009)
Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin:: Multivariate analysis of data from four randomized CUETO trials
Jesus Fernandez-Gomez et al.
EUROPEAN UROLOGY (2008)
History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story
Harry W. Herr et al.
JOURNAL OF UROLOGY (2008)
Bacillus Calmette-Guerin-pulsed dendritic cells stimulate natural killer T cells and γδT cells
Michio Naoe et al.
INTERNATIONAL JOURNAL OF UROLOGY (2007)
Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
Marcia R. Saban et al.
BMC IMMUNOLOGY (2007)
Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery
I. A. Khalil et al.
GENE THERAPY (2007)
Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guerin through Toll-like receptor signalling
J Miyazaki et al.
BJU INTERNATIONAL (2006)
High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression
IA Khalil et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Complications of intravesical therapy for urothelial cancer of the bladder
Madhusudan P. Koya et al.
JOURNAL OF UROLOGY (2006)
Bladder cancer: Epidemiology, staging and grading, and diagnosis
Z Kirkali et al.
UROLOGY (2005)
A multifunctional envelope-type nano device for novel gene delivery of siRNA plasmids
R Moriguchi et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2005)
Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials
RJ Sylvester et al.
JOURNAL OF UROLOGY (2005)
Bladder carcinoma in situ in 2003: State of the art
JA Witjes
EUROPEAN UROLOGY (2004)
Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method
K Kogure et al.
JOURNAL OF CONTROLLED RELEASE (2004)
Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy
F Saint et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder
E Watanabe et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2003)
A clinical study of PMCJ-9 (Bacillus Calmette-Guerin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder
H Akaza et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2003)
Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity
R Nadler et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2003)
Spectrum of Bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy
OY Gonzalez et al.
CLINICAL INFECTIOUS DISEASES (2003)
Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer
A Kumar et al.
JOURNAL OF UROLOGY (2002)
Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guerin (BCG): A role of BCG internalization into tumor cells
N Ikeda et al.
INTERNATIONAL JOURNAL OF UROLOGY (2002)
Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer
F Saint et al.
JOURNAL OF UROLOGY (2002)
The fate of bacillus Calmette-Guerin after intravesical instillation
C Durek et al.
JOURNAL OF UROLOGY (2001)
Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer
F Saint et al.
UROLOGY (2001)
Trehalose 6,6′-dimycolate (Cord factor) of Mycobacterium tuberculosis induces foreign-body- and hypersensitivity-type granulomas in mice
H Yamagami et al.
INFECTION AND IMMUNITY (2001)
Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin
GN Thalmann et al.
JOURNAL OF UROLOGY (2000)
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study
DL Lamm et al.
JOURNAL OF UROLOGY (2000)
Bacterial modulation of antigen processing and presentation
WP Maksymowych et al.
MICROBES AND INFECTION (2000)
Glycosaminoglycan content of human bladders: a method of analysis using cold-cup biopsies
MM Poggi et al.
UROLOGIC ONCOLOGY (2000)
BCG intravesical instillations: Recommendations for side-effects management
P Rischmann et al.
EUROPEAN UROLOGY (2000)
分享论文
